The estimated Net Worth of Claudia Ordonez is at least $54.8 Mille dollars as of 11 June 2021. Claudia Ordonez owns over 1,000 units of Keros Therapeutics stock worth over $54,750 and over the last 5 years Claudia sold KROS stock worth over $0.
Claudia has made over 5 trades of the Keros Therapeutics stock since 2021, according to the Form 4 filled with the SEC. Most recently Claudia exercised 1,000 units of KROS stock worth $480 on 11 June 2021.
The largest trade Claudia's ever made was exercising 1,000 units of Keros Therapeutics stock on 11 June 2021 worth over $480. On average, Claudia trades about 714 units every 17 days since 2020. As of 11 June 2021 Claudia still owns at least 1,000 units of Keros Therapeutics stock.
You can see the complete history of Claudia Ordonez stock trades at the bottom of the page.
Claudia's mailing address filed with the SEC is C/O KEROS THERAPEUTICS, INC., 99 HAYDEN AVENUE, SUITE 120, BUILDING E, LEXINGTON, MA, 02421.
Over the last 5 years, insiders at Keros Therapeutics have traded over $50,765,607 worth of Keros Therapeutics stock and bought 2,504,088 units worth $46,191,339 . The most active insiders traders include Ran Nussbaum, Carl L Gordon e Tomer Kariv. On average, Keros Therapeutics executives and independent directors trade stock every 25 days with the average trade being worth of $3,312,649. The most recent stock trade was executed by Carl L Gordon on 13 August 2024, trading 250,000 units of KROS stock currently worth $11,002,500.
Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need. The company's lead protein therapeutic product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, and in patients with myelofibrosis. It is also developing small molecule product candidate KER-047 that is being developed for the treatment of anemia, and is currently in Phase 1 clinical trial; and KER-012, which is in Phase 1 clinical trial to treat disorders associated with bone loss, such as osteoporosis and osteogenesis imperfecta, and for the treatment of pulmonary arterial hypertension. The company was incorporated in 2015 and is headquartered in Lexington, Massachusetts.
Keros Therapeutics executives and other stock owners filed with the SEC include: